{
    "clinical_study": {
        "@rank": "117476", 
        "brief_summary": {
            "textblock": "RATIONALE: Studying plasma samples from patients with pancreatic cancer in the laboratory\n      may help doctors identify and learn more about biomarkers related to cancer.\n\n      PURPOSE: This research trial studies biomarkers in samples from patients with pancreatic\n      cancer treated on study CALGB-80303."
        }, 
        "brief_title": "Biomarkers in Plasma Specimens From Patients Treated on Study CALGB-80303", 
        "condition": "Pancreatic Cancer", 
        "condition_browse": {
            "mesh_term": "Pancreatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  To determine whether the observed predictive value of plasma VEGF-A and VEGF-R2 for\n           overall survival (OS) in study BO17706 can be replicated in study CALGB-80303 using the\n           same Immunological Multiparameter Chip Technology (IMPACT) assay.\n\n        -  To determine whether the observed predictive value of plasma VEGF-A and VEGF-R2 for\n           progression-free survival (PFS), and other circulating biomarkers in study BO17706, can\n           be replicated in study CALGB-80303 using the same IMPACT assay.\n\n        -  To explore the relationship between efficacy and other biomarkers measured in the\n           plasma samples.\n\n      OUTLINE: The samples required for this study are stored in the CALGB Pathology Coordinating\n      Office at The Ohio State University from patients enrolled on protocol CALGB-80303. No\n      additional samples are required from patients.\n\n      The following markers are analyzed in EDTA plasma samples using the Immunological\n      MultiParameter Chip Technology (IMPACT) a Roche proprietary multiplex enzyme-linked\n      immunosorbent assay (ELISA) platform: VEGF-A, VEGF-C, VEGF-R1, VEGF-R2, E-selectin, VEGF-R3,\n      IL-8, bFGF, PDGF-C, ICAM-1, and PlGF."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Patients must have been registered to CALGB-80303\n\n               -  Histologically or cytologically confirmed adenocarcinoma of the pancreas\n\n               -  Locally advanced or metastatic disease\n\n        PATIENT CHARACTERISTICS:\n\n          -  Not specified\n\n        PRIOR CONCURRENT THERAPY:\n\n          -  See Disease Characteristics"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01664169", 
            "org_study_id": "A151201", 
            "secondary_id": [
                "CDR0000738204", 
                "NCI-2012-01994"
            ]
        }, 
        "intervention": [
            {
                "intervention_name": "enzyme-linked immunosorbent assay", 
                "intervention_type": "Other"
            }, 
            {
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "adenocarcinoma of the pancreas", 
            "recurrent pancreatic cancer", 
            "stage III pancreatic cancer", 
            "stage IV pancreatic cancer", 
            "stage IIB pancreatic cancer"
        ], 
        "lastchanged_date": "June 17, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/CALGB-A151201"
        }, 
        "official_title": "Validation of Circulating Biomarkers Using the Immunological Multiparameter Chip Technology (IMPACT) on Plasma Specimens Collected on CALGB 80303", 
        "overall_official": {
            "affiliation": "CALGB Statistical Office at Duke University Medical Center", 
            "last_name": "Herbert Pang, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_outcome": [
            {
                "measure": "Median OS/PFS (95% CI) estimated from Kaplan-Meier curves for patients with low and patients with high biomarker levels", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Stratified OS/PFS hazard ratio (HR) (95% CI) from the Cox model for patients with low and patients with high biomarker levels", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Stratified OS/PFS HR (95% CI) from Cox model by quartile of VEGF-A levels", 
                "safety_issue": "No"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01664169"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Number and percentage of responders and the stratified objective response (OR) from logistic regression for patients with high and low concentration of biomarker", 
            "safety_issue": "No"
        }, 
        "source": "Alliance for Clinical Trials in Oncology", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Cancer and Leukemia Group B", 
                "agency_class": "Other"
            }
        }, 
        "study_design": "N/A", 
        "study_type": "Observational", 
        "verification_date": "August 2012"
    }
}